Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

喜开悦 - NMPA Drug Approval Details

Approvals/NMPA/Risankizumab Injection (Subcutaneous Injection)

Approved

生物制品

Risankizumab Injection (Subcutaneous Injection)

Unknown🇨🇳 National Medical Products Administration

Approval Date: Jan 14, 2026
Approval ID: 8mdl9Hqxpaj
Company: Unknown
Type: 生物制品

Approval Details

Approval Id: 8mdl9Hqxpaj
Approval Number: 国药准字SJ20260002
Generic Name: 利生奇珠单抗注射液(皮下注射)
Generic Name En: Risankizumab Injection (Subcutaneous Injection)
Trade Name: 喜开悦
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 180 mg（1.2 mL）/支
Reg Date: 2026-01-14
Expired Date: 2031-01-13

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jan 14, 2026

Approval ID

8mdl9Hqxpaj

Type

生物制品

Back to NMPA Approvals